Treatment-free survival after two-year immune checkpoint inhibitor treatment in non-small cell lung cancer: Utilizing the Korean Health Insurance Review and Assessment Service database
- 8 June 2026
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 218, 109490
Abstract
No abstract availableKeywords
Funding Information
- College of Medicine, Korea University (K2327231)
- College of Medicine, Korea University (K2505651)
This publication has 28 references indexed in Scilit:
- Outcomes and Treatments of Patients With Non–Small Cell Lung Cancer Who Received PembrolizumabJAMA Oncology, 2026
- Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP studyEuropean Journal of Cancer, 2026
- Thyroid disorders induced by immune checkpoint inhibitorsEndocrine, 2024
- Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung CancerJAMA Oncology, 2023
- Continuous vs. Fixed 2-year Duration Immune Checkpoint Inhibitor Treatment of Patients With Non–Small Cell Lung Cancer: A Single Institution Database AnalysisClinical Lung Cancer, 2023
- Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced MelanomaJAMA Network Open, 2023
- Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint InhibitorsThe Oncologist, 2021
- Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%Cancer Immunology, Immunotherapy, 2020
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-AnalysisJournal of Thoracic Oncology, 2017
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987